Citigroup Inc. increased its holdings in shares of C.R. Bard, Inc. (NYSE:BCR) by 100.7% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 114,620 shares of the medical instruments supplier’s stock after purchasing an additional 57,501 shares during the quarter. Citigroup Inc. owned 0.16% of C.R. Bard worth $36,232,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in C.R. Bard by 70.4% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 190 shares in the last quarter. Parallel Advisors LLC increased its position in C.R. Bard by 283.8% during the 1st quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock worth $153,000 after purchasing an additional 369 shares in the last quarter. ClariVest Asset Management LLC acquired a new stake in C.R. Bard during the 1st quarter worth approximately $148,000. SRS Capital Advisors Inc. increased its position in C.R. Bard by 0.7% during the 1st quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after purchasing an additional 4 shares in the last quarter. Finally, Captrust Financial Advisors acquired a new stake in C.R. Bard during the 2nd quarter worth approximately $192,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently issued reports on BCR shares. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 target price for the company in a research report on Tuesday, June 6th. BidaskClub downgraded shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. BMO Capital Markets reissued a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. Finally, Jefferies Group LLC reissued a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $292.00.

WARNING: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/19/c-r-bard-inc-bcr-shares-bought-by-citigroup-inc.html.

C.R. Bard, Inc. (BCR) traded down 0.28% during trading on Tuesday, reaching $318.62. The company’s stock had a trading volume of 88,320 shares. The stock’s 50-day moving average is $320.14 and its 200 day moving average is $298.69. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $324.58. The firm has a market capitalization of $23.15 billion, a price-to-earnings ratio of 41.83 and a beta of 0.60.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. During the same quarter last year, the firm earned $2.54 EPS. C.R. Bard’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, analysts predict that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.

In other news, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the sale, the insider now owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.80% of the stock is currently owned by company insiders.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.